Buspirone treatment of psychiatrically hospitalized prepubertal children with symptoms of anxiety and moderately severe aggression

Journal of Child and Adolescent Psychopharmacology

Volumn 7, Issue 3, 1997, Pages 145-155

  Pfeffer, Cynthia R ^a,b   Jiang, Hong ^a   Domeshek, Lisa J ^a  

^a WEILL CORNELL MEDICAL CENTER   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSPIRONE; LITHIUM; NEUROLEPTIC AGENT;

AGGRESSION; ANXIETY NEUROSIS; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DEPRESSION; FEMALE; HOSPITALIZATION; HUMAN; MALE; MOOD; PATIENT; RAGE; SUICIDAL BEHAVIOR; VIOLENCE;

EID: 0031422295     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.1997.7.145     Document Type: Article

References (28)

1. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised (DSM-III-R). Washington, D.C., American Psychiatric Association, 1987
2. Bass JW, Geenens DL, Popper C: Measure of Aggression, Violence, and Rage in Children (MAVRIC) [abstract]. Proceedings of the Annual Meeting of the American Academy of Child and Adolescent Psychiatry, San Francisco (CA), October, 1993
3. Campbell M, Adams PB, Small AM, Kafantaris V, Silva RR, Shell J, Perry R, Overall JD: Lithium in hospitalized aggressive children with conduct disorder: A double-blind and placebo-controlled study. J Am Acad Child Adolesc Psychiatry 34:445-453, 1995
4. Campbell M, Small A, Green WH, Jennings SJ, Perry R, Bennett WG, Anderson L: Behavioral efficacy of haloperidol and lithium carbonate: A comparison in hospitalized aggressive children with conduct disorder. Arch Gen Psychiatry 41:650-656, 1984
5. Chiaie RD, Pancheri P, Casacchia M, Stratta P, Kotzalidis GD, Zibellini M: Assessment of the efficacy of buspirone in patients affected by generalized anxiety disorder, shifting to buspirone from prior treatment with lorazepam: A placebo-controlled, double-blind study. J Clin Psychopharmacol 15:12-19, 1995
6. Cohen J: A coefficient of agreement for nominal scales. Educational Psychological Measures 20:37-46, 1960
7. Goldberg HL, Finnerty R: Comparison of buspirone in two separate studies. J Clin Psychiatry 43:87-91, 1982
8. Gross MD: Buspirone in ADHD with ODD [letter]. J Am Acad Child Adolesc Psychiatry 34:1260, 1995
9. Hollingshead HM, Redlich P: Social Class and Mental Illness. New York, Wiley, 1958
10. Kovacs M: Rating scales to assess depression in school-age children. Acta Paedopsychiatrica 46:305-315, 1980
11. Kranzler HR: Use of buspirone in an adolescent with overanxious disorder. J Am Acad Child Adolesc Psychiatry 27:789-790, 1988
12. Markovitz PJ, Stagno SJ, Calabrese JR: Buspirone augmentation of fluoxetine in obsessive compulsive disorder. Am J Psychiatry 147:798-800, 1990
13. Pfeffer CR: The Suicidal Child. New York, Guilford Press, 1986
14. Pfeffer CR, Plutchik R, Mizruchi MS, Lipkins R: Suicidal behavior in child psychiatric inpatients, and outpatients and in nonpatients. Am J Psychiatry 43:733-738, 1986
15. Quiason N, Ward D: Buspirone for aggression [letter]. J Am Acad Child Adolesc Psychiatry 30:1026, 1991
16. Ratey JJ, Sovner R, Mikkelsen E, Chielinsky HE: Buspirone therapy for maladaptive behavior and anxiety in developmentally disabled persons. J Clin Psychiatry 50:382-384, 1980
17. Realmuto GM, August GJ, Garfinkel BD: Clinical effect of buspirone in autistic children. J Clin Psychopharmacol 9:122-125, 1989
18. Reynolds CR, Richmond BO: Revised Children's Manifest Anxiety Scale (RCMAS) Manual. Los Angeles (CA), Western Psychological Services, 1985
19. Robinson DS, Rickels K, Feighner J, Fabre L, Gammans R, Shrotriya R, Alms D, Andary J, Messina M: Clinical effects of the 5-HT(1a) partial agonists in depression: A composite analysis of buspirone in the treatment of depression. J Clin Psychopharmacol 10 (Suppl) 67S-76S, 1990
20. Scandinavian Society of Psychopharmacology, Committee of Clinical Investigations (UKU): The UKU Side Effects Rating Scale: Scale for the Registration of Unwanted Effects of Psychotropics Manual. Oslo, Norway, 1986
21. Schneier FR, Saoud JB, Campeas R, Fallon BA, Hollander E, Coplan J, Lieboowitz MR: Buspirone in social phobia. J Clin Psychopharmacol 13:251-256, 1993
22. Shaffer D, Gould MS, Brasic J, Ambrosini P, Fisher P, Bird H, Aluwahlia S: A Children's Global Assessment Scale (CGAS). Arch Gen Psychiatry 40:1228-1231, 1983
23. Silver JM, Yudofsky SC: The Overt Aggression Scale: Overview and guiding principles. J Neuropsychiatry 3 (Suppl):22-29, 1991
24. Simeon JG, Knott VJ, Dubois C, Wiggins D, Geraets I, Thatte S, Miller W: Buspirone therapy of mixed anxiety disorders in childhood and adolescence: A pilot study. J Child Adolesc Psychopharmacol 4:159-170, 1994
25. Sramek JJ, Tansman M, Suri A, Hornig-Rohan M, Amsterdam JD, Stahl SM, Weisler RH, Cutler NR: Efficacy of buspirone in generalized anxiety disorder with coexisting mild depressive symptoms. J Clin Psychiatry 57:287-291, 1996
26. van Vliet IM, den Boer JA, Westenberg HGM, Pian KLH: Clinical effects of buspirone in social phobia: A double-blind placebo-controlled study. J Clin Psychiatry 58:164-168, 1997
27. Wheatley D: Buspirone: Multicenter efficacy study. J Clin Psychiatry 43:92-94, 1982
28. Zwier, KJ, Rao U: Buspirone use in an adolescent with social phobia and mixed personality disorder (Cluster A type). J Am Acad Child Adolesc Psychiatry 33:1007-1011, 1994